Search Results 211-220 of 17206 for peptide combinations

  1. Oncology (Medical) - Clinical trials

    The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS. All ...

  2. Pertuzumab, trastuzumab, and hyaluronidase-zzxf (subcutaneous route) - Side effects & uses - Mayo Clinic

    Description. Pertuzumab, trastuzumab, and hyaluronidase-zzxf combination injection is used first together with other cancer medicines to treat HER2-positive ...

  3. Clinical trials - Oncology (Medical)

    Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...

  4. Mayo Clinic expert highlights improved survival in muscle-invasive bladder cancer and kidney cancer

    Zakharia says the combination may soon become standard therapy before surgery for patients eligible to receive cisplatin. Improving outcomes in kidney cancer.

  5. Hematology - Clinical trials

    Giving ascorbic acid and combination chemotherapy may work better at treating lymphoma. In the Clonal Cytopenia of Undetermined Significance (CCUS) Cohort D, we ...

  6. Clinical trials - Oncology (Medical)

    Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...

  7. Clinical trials - Oncology (Medical)

    Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...

  8. Clinical trials - Oncology (Medical)

    This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor ...

  9. A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies - Mayo Clinic

    A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in ...

  10. Clinical trials - Oncology (Medical)

    The purpose of this study is to evaluate how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic ...